While not yet widely adopted, diflunisal, anonsteroidal anti-inflammatory drug with TTR-stabilizing properties, has shownbeneficial effects in small observational studies and early trials, particularlyin slowing neuropathy progression in ATTRv with predominant neuropathy, thoughits use is limited by safety concerns (e.g., renal and gastrointestinal toxicity)and lack of large-scale randomized controlled trial (RCT) data. The gene discussed is TTR; the disease is neuropathy.